Vascular scaffolds are engineered structures designed to guide the regeneration of blood vessels. Among the most critical determinants of long-term graft success is the establishment of a functional endothelial layer on the scaffold surface. Endothelialization—the process by which endothelial cells (ECs) adhere, proliferate, and form a confluent monolayer—directly influences thrombogenicity, patency, and integration with host tissue. Without rapid and stable endothelial coverage, synthetic and tissue-engineered vascular grafts are prone to early failure from thrombosis and late failure from intimal hyperplasia. This article outlines the key strategies to promote endothelialization, from surface chemistry and topography to bioactive factor delivery and cell seeding, and examines emerging technologies that promise to bring fully functional vascular grafts closer to clinical reality.

The Importance of Endothelialization in Vascular Grafts

The endothelium is a dynamic, metabolically active barrier that regulates hemostasis, inflammation, and vascular tone. In native arteries, ECs produce anti-thrombotic molecules such as prostacyclin and nitric oxide, prevent leukocyte adhesion, and control smooth muscle cell proliferation. When a vascular scaffold is implanted, the absence of this endothelial lining exposes the underlying material to blood, triggering platelet activation and coagulation cascades. Even transient exposure can seed clot formation and lead to acute occlusion. Over time, the lack of EC coverage also stimulates excessive smooth muscle cell migration and extracellular matrix deposition, manifesting as intimal hyperplasia and eventual graft stenosis.

A confluent endothelium achieves three essential functions: it provides a non-thrombogenic blood-contacting surface, regulates the permeability of the vessel wall, and secretes paracrine signals that maintain vessel homeostasis. Thus, any strategy that accelerates and stabilizes endothelialization can dramatically improve graft patency, especially in small-diameter (<6 mm) applications where flow dynamics are less favorable and the risk of thrombosis is highest. Clinical and experimental evidence consistently shows that grafts with faster endothelialization exhibit lower rates of occlusion, reduced infection, and better long-term outcomes.

Key Strategies to Promote Endothelialization

Approaches to enhance endothelialization address the scaffold–blood interface at multiple levels—from passive material properties to active biological interventions. The most effective strategies often combine several of the following tactics to create a conducive microenvironment for EC attachment, migration, and proliferation.

Surface Modification with Bioactive Coatings

Coating the scaffold lumen with molecules that mimic the native extracellular matrix (ECM) or that directly interact with EC integrins is a widely investigated strategy. Common coatings include:

  • Collagen and gelatin: These natural proteins contain RGD sequences that promote integrin-mediated EC adhesion. Collagen coatings have been shown to enhance EC coverage and reduce activation of platelets.
  • Laminin and fibronectin: Laminin, a key component of the vascular basement membrane, particularly supports EC adhesion and migration. Fibronectin also encourages cell spreading and cytoskeletal organization.
  • Heparin and other glycosaminoglycans: Immobilized heparin can bind growth factors (e.g., VEGF, FGF) and sequester them at the surface, providing a sustained mitogenic stimulus while also exerting local anticoagulant effects.
  • Peptide coatings (RGD, REDV, YIGSR): Short synthetic peptides avoid the immunogenicity and batch variability of whole proteins. RGD (Arg-Gly-Asp) is the most used, but vascular-specific sequences like REDV (Arg-Glu-Asp-Val) from fibronectin and YIGSR (Tyr-Ile-Gly-Ser-Arg) from laminin show selective EC adhesion over smooth muscle cells, a valuable property for reducing neointimal hyperplasia.

Biomimetic Materials and Natural ECM Scaffolds

Instead of coating a synthetic polymer, the scaffold itself can be made from materials that closely resemble the native ECM. Decellularized vascular matrices retain the native architecture, including the basement membrane and growth factor reservoir, providing an ideal template for endothelialization. Synthetic biomimetic polymers such as polycaprolactone (PCL) blended with elastin or collagen, or polyurethanes with soft segments that mimic ECM elasticity, can be tailored to match the mechanical properties of native arteries while offering surface chemistries that favor EC adhesion. Electrospinning these materials produces nanofibrous scaffolds that further mimic the fibrillar structure of the ECM, enhancing cell guidance and attachment.

Growth Factor Delivery and Controlled Release

Providing the right growth factors at the right time is a powerful way to accelerate endothelialization. Vascular endothelial growth factor (VEGF) is the primary stimulator of EC proliferation, migration, and tube formation. Basic fibroblast growth factor (bFGF) and platelet-derived growth factor (PDGF) also play supportive roles. Delivery strategies include:

  • Physical adsorption or covalent immobilization: Growth factors can be adsorbed onto the scaffold surface or covalently bound via linkers that release them upon cell-mediated enzymatic cleavage.
  • Encapsulation in microspheres or nanocarriers: Growth factors loaded into PLGA microspheres or lipid nanoparticles can be embedded within the scaffold wall, providing sustained release over weeks to months.
  • Heparin-binding systems: Heparin-immobilized scaffolds can reversibly bind heparin-binding growth factors like VEGF and bFGF, allowing slow release as the heparin exchanges with endogenous proteins.
  • Dual delivery: Some studies show that sequential release of PDGF (to recruit smooth muscle cells and pericytes) followed by VEGF (to stabilize the endothelium) can produce more stable and mature vascular structures. However, careful timing is required to avoid stimulating unwanted cell populations.

Recent reviews have highlighted that while VEGF is potent, high local concentrations can lead to leaky, malformed vessels. Controlled release profiles that mimic natural temporal cues—such as an initial burst followed by sustained low-level release—tend to produce more functional endothelium. Studies using VEGF-loaded PLGA nanoparticles in electrospun PCL scaffolds have shown complete endothelialization within 14 days in a rabbit carotid model.

Cell Seeding and Pre-Endothelialization

Pre-seeding the scaffold with autologous endothelial cells before implantation is one of the most direct methods to achieve complete endothelialization. Cells can be harvested from a small biopsy of the patient’s own vein or from adipose-derived stem cells differentiated into endothelial-like cells. Seeding techniques must ensure uniform distribution and strong adhesion. Dynamic seeding in a rotating bioreactor or under flow conditions produces more homogeneous coverage than static seeding. After seeding, the construct may be preconditioned under pulsatile flow to align ECs in the direction of flow, upregulate shear-responsive genes, and reduce the risk of cell detachment upon implantation.

Limitations of cell seeding include the need for a second surgical procedure for cell harvest, the time required to expand cells in culture (typically 2–4 weeks), and the risk of contamination or dedifferentiation. To address these, researchers are developing “off-the-shelf” allogeneic EC lines that are hypoimmunogenic, such as those engineered to lack MHC class II molecules, or using cord-blood-derived endothelial colony-forming cells (ECFCs) that can be cryopreserved and thawed on demand. A recent study demonstrated that ECFC-seeded small-diameter vascular grafts achieved patency rates >90% in a porcine model after 6 months.

Surface Topography and Micro/Nano-Patterning

Endothelial cells are highly sensitive to the physical features of the underlying substrate. Topographical cues at the micro- and nano-scale can guide cell alignment, enhance focal adhesion formation, and promote migration. Techniques to create such features include:

  • Electrospinning with aligned fibers: Nanofibers aligned parallel to the vessel axis induce ECs to elongate and migrate directionally, mimicking the in vivo morphology.
  • Photolithography and etching: These methods create precise grooves, ridges, or pillars of defined dimensions. Grooves 1–5 μm wide and 0.5–2 μm deep have been shown to significantly improve EC alignment and speed of migration compared to flat surfaces.
  • Nanoparticle decoration: Gold, silica, or hydroxyapatite nanoparticles deposited on the scaffold surface increase surface roughness and provide additional integrin-binding sites, enhancing EC adhesion without altering bulk mechanical properties.
  • Gradient topographies: Scaffolds with a gradient of feature sizes can induce haptotaxis—directional migration of ECs toward regions of higher adhesion or stiffness—which can be used to guide cell ingrowth from the anastomotic ends.

It is important to note that while rough surfaces can enhance EC adhesion, they also increase platelet activation if the pores are larger than ~5 μm or if the roughness geometry traps platelets. Optimal topography balances EC stimulation with minimal thrombogenicity.

Mechanical Conditioning and Hemodynamic Simulation

The mechanical environment of the graft profoundly influences endothelialization. Native ECs respond to shear stress by elongating, aligning, and upregulating anti-thrombotic genes. Implanted scaffolds that are highly compliant may cause abnormal flow patterns that delay endothelialization and promote intimal hyperplasia. Strategies to mimic physiological hemodynamics include:

  • Preconditioning in flow bioreactors: Exposing seeded scaffolds to pulsatile shear stress (10–20 dyne/cm²) for several days before implantation enhances EC retention and induces a mature, quiescent phenotype.
  • Scaffold compliance matching: Designing grafts with elastic moduli similar to native arteries reduces compliance mismatch at the anastomosis, which in turn reduces flow disturbances and promotes rapid endothelialization.
  • In situ endothelialization using microtextured surfaces that capture circulating endothelial progenitor cells (EPCs): This approach draws on the natural ability of EPCs to home to sites of vascular injury. Scaffolds coated with antibodies against EPC markers (e.g., CD34, VEGFR-2) or with adhesion peptides that specifically attract EPCs can achieve rapid in situ endothelialization without ex vivo cell culture. A clinical trial using CD34-antibody-coated ePTFE grafts showed enhanced EPC capture and improved patency in below-knee bypass grafts.

Emerging Technologies and Future Directions

The next generation of vascular scaffolds will likely integrate multiple cues—chemical, topographical, mechanical, and biological—in a spatiotemporally controlled manner. Several emerging technologies are poised to push endothelialization strategies further.

Nanotechnology and Nanocarriers

Nanoparticles can deliver bioactive molecules with high precision. For example, VEGF-loaded mesoporous silica nanoparticles embedded in the scaffold can release the growth factor in response to pH changes that occur during inflammation, providing targeted release at the early stages of wound healing. Similarly, nitric-oxide-donating nanoparticles can supply this critical anti-thrombotic molecule locally, promoting both endothelialization and vasodilation. Nanotopography created by carbon nanotubes or graphene oxide sheets can also be used to tune EC alignment and proliferation through electrical stimulation, since ECs respond to low-level electric fields by migrating toward the cathode (galvanotaxis).

3D Bioprinting and Patient-Specific Scaffolds

Additive manufacturing enables the fabrication of scaffolds with controlled porosity, hierarchical architecture, and compositional gradients. 3D bioprinting can deposit living cells, growth factors, and biomaterials simultaneously, creating constructs that contain pre-vascularized channels. Using patient-specific imaging data, one can print a scaffold that exactly matches the dimensions of the target artery, ensuring optimal hemodynamics. Bioprinting also allows the incorporation of perfusable microchannels that can be lined with ECs, serving as a template for rapid anastomosis and blood flow. Recent work bioprinted a small-diameter vascular graft with a dual-layer structure: an outer layer of smooth muscle cells in gelatin methacryloyl and an inner layer of ECs in a fibrin-hyaluronic acid ink, achieving >95% endothelial coverage after 7 days of perfusion culture.

Smart Biomaterials and Responsive Substrates

Materials that respond to environmental stimuli—such as pH, temperature, enzymes, or light—offer dynamic control over endothelialization. For example, thermoresponsive polymers like poly(N-isopropylacrylamide) (PNIPAAm) can be used to create a surface that switches from adhesive to non-adhesive at body temperature, enabling controlled cell sheet harvest for layered constructs. Enzyme-responsive hydrogels can be designed to release VEGF only when matrix metalloproteinases (MMPs) secreted by migrating ECs degrade the gel, providing an auto-regulatory feedback loop. Such systems can prevent overdosing of growth factors while ensuring that release coincides with cell invasion.

Gene Therapy and Epigenetic Modulation

Delivery of pro-endothelialization genes directly into the cells lining the scaffold represents a promising alternative. Using viral vectors (e.g., adenovirus, lentivirus) or non-viral nanoparticles to transfect ECs or EPCs with VEGF, eNOS (endothelial nitric oxide synthase), or transcription factors like KLF2 can produce sustained expression of proteins that promote endothelialization. Epigenetic modifiers, such as histone deacetylase inhibitors, can also be used to upregulate EC-specific genes and improve the function of seeded cells. However, safety concerns regarding off-target effects and long-term expression remain areas of active research.

Challenges and Considerations

Despite the wealth of strategies, translating endothelialization methods from bench to bedside faces several hurdles. The ideal strategy must be scalable, cost-effective, and compatible with regulatory requirements. Many surface modification techniques are complex and difficult to reproduce in a clinical setting. Pre-seeding with autologous cells is limited by the availability of donor tissue and the time needed for cell expansion. In situ EPC capture, while simpler, relies on the patient’s own circulating EPC numbers, which are reduced in elderly or diabetic patients—precisely the population that most needs vascular grafts.

Another challenge is the balance between promoting EC growth and inhibiting smooth muscle cell proliferation. Many growth factors and adhesion peptides that encourage ECs also activate smooth muscle cells, potentially worsening intimal hyperplasia. Developing strategies with true cell-type selectivity remains a high priority. Additionally, long-term stability of the endothelial layer under physiological shear stress and cyclical mechanical strain must be demonstrated. In vivo animal models, while informative, may not fully predict human responses, and larger animal studies are needed before clinical trials.

Integrating Multiple Strategies for Optimal Outcomes

No single approach is likely to achieve rapid, stable, and complete endothelialization in all clinical scenarios. Rather, the most successful grafts will combine complementary strategies. For example, a scaffold made from a biomimetic polyurethane blend, featuring aligned nanofibers, covalently immobilized heparin, and a slow-release VEGF formulation, can simultaneously provide topographical guidance, anticoagulant activity, and mitogenic stimulation. Pre-seeding that scaffold with autologous ECFCs and preconditioning under pulsatile flow could produce a graft that is ready to function immediately upon implantation. Research into such integrated systems is ongoing, and early results are encouraging.

Looking Ahead

The field of vascular tissue engineering is moving toward smart, patient-specific grafts that actively participate in their own integration. Advances in computational modeling, real-time biosensing, and feedback-controlled release systems will allow future scaffolds to adapt to the healing environment. For instance, a graft could sense the presence of thrombin (indicating clot formation) and release urokinase to dissolve the clot while simultaneously upregulating VEGF delivery to accelerate endothelial repair. Although such sophistication is still in the laboratory phase, the rapid pace of innovation suggests that fully functional, long-lasting vascular scaffolds with robust endothelialization will become a clinical reality within the next decade.

Ultimately, the goal is to restore normal vascular function with a graft that is not merely tolerated by the body but actively remodeled into a living, self-repairing conduit. Achieving that goal depends on continued refinement of endothelialization strategies—and on the creative integration of materials science, cell biology, and engineering principles.